[Click e-Stock] "JLK to Reach Performance Turning Point in 2026 with Full-Scale Expansion into US and Japan"

On January 13, Hanyang Securities analyzed that JLK is expected to reach a turning point in its performance this year as it begins full-scale expansion into the United States and Japan.

Lee Junseok, a researcher at Hanyang Securities, stated, "In the past, when patients visited hospitals, they had no choice but to rely entirely on the physician's experience and judgment. Now, at least in the field of diagnostics, AI is emerging at the forefront of medical practice. In the United States, the number of imaging tests is surging, while the supply of specialists remains limited. In this environment, where both speed and accuracy are required, AI is becoming an essential infrastructure, not a choice."

In particular, stroke is a condition that is highly dependent on imaging and is difficult to interpret, meaning that even a few seconds of diagnostic delay or a misdiagnosis can have fatal consequences. Lee noted, "Major hospitals in the United States are actively adopting AI-based automated stroke imaging interpretation and quantification solutions. In fact, stroke AI solutions are analyzing millions of images annually, and medical AI is already being integrated into routine clinical practice." He further emphasized, "The spread of medical AI is not about replacing doctors, but about restructuring the very framework of medical decision-making, and this transformation is becoming a reality first in the field of stroke diagnosis."

JLK, with a portfolio of 12 solutions covering the entire stroke care continuum from emergency, diagnosis, to rehabilitation, has established a differentiated structure compared to competitors focusing on just three to four solutions. By inputting CT and MRI imaging data, the system can quantitatively analyze the location and severity of lesions, and it can be integrated with hospital PACS and EMR systems, allowing implementation without additional workflow changes-another key strength.

Lee explained, "JLK is the leading domestic company capable of providing end-to-end AI solutions for stroke care. The company has quickly secured regulatory approvals and expanded hospital installations, accumulating references from over 210 hospitals." Notably, at the end of 2023, JLK-DWI became the first AI solution in the field to receive approval for innovative medical technology as a non-reimbursed item, which led to the start of significant revenue generation last year. As of 2025, the company has secured registrations at 76 hospitals with the Health Insurance Review and Assessment Service, and with further expansion, domestic revenue in 2026 is also expected to enter a phase of rapid growth.

JLK is not only strengthening its position in the domestic market but is also making visible progress in entering the Japanese and U.S. markets. The company has spent years preparing to obtain the first non-reimbursed code for innovative medical technology in the field of medical AI, securing six FDA 510(k) clearances in the United States and seven PMDA approvals in Japan. Lee commented, "Due to external factors such as medical strikes and delays in certification from foreign regulatory agencies, it took longer than expected for actual revenue to materialize. However, compared to the company's mid- to long-term roadmap, the direction and goals have been achieved sequentially and with certainty."

In particular, JLK has established a foundation for entry into the Japanese market by signing a distribution agreement with the Marubeni Group, and revenue is also expected to be generated in the United States starting in the second half of the year. Lee projected, "In 2026, revenue is expected to reach 4.5 billion won in Korea, 5 billion won in Japan, and 3.5 billion won in the United States, totaling approximately 13 billion won. Considering the concentration of revenue in the second half, there is also a possibility of reaching the quarterly break-even point."